Skip to Content

Join the 'Votrient' group to help and get support from people like you.

Votrient News

Many Cancer Patients Skimp on Treatment Due to Cost

Posted 24 Oct 2017 by Drugs.com

TUESDAY, Oct. 24, 2017 – The high cost of cancer care in the United States has led more than one-quarter of patients to cut back on some part of their treatment, a new survey reveals. Commissioned by the American Society of Clinical Oncology (ASCO), the report found that 27 percent of cancer survivors or close relatives of a cancer patient said they'd skipped doctor visits or taken other steps to reduce health costs. To save money, nearly one in 10 said they had avoided doctor appointments. Eight percent had refused treatment; postponed filling or not filled prescriptions; or skipped doses of prescribed medications. And 7 percent said they had cut pills in half, according to the survey of more than 4,000 adults. Such measures can jeopardize treatment success, ASCO says. "We should all be alarmed that Americans are potentially risking not only their health, but also their lives, due to ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Fluorouracil, Femara, Lung Cancer, Gleevec, Colorectal Cancer, Non-Small Cell Lung Cancer, Anastrozole, Zoladex, Votrient, Letrozole

More Patients OK'd for Cancer Trials Under Obamacare: Study

Posted 20 Jul 2017 by Drugs.com

THURSDAY, July 20, 2017 – The Affordable Care Act has enabled more privately insured patients to enroll in clinical trials for new cancer treatments, a new study contends. Speedy approvals are important for patients who want to participate in clinical trials, said study author Dr. David Hong. He's deputy chair of investigational cancer therapeutics at the University of Texas MD Anderson Cancer Center. Since 2000, Medicare, the publicly funded insurance program for seniors, has covered routine costs of clinical trial participation. But coverage for patients with private insurance differed by insurer and state, the researchers noted. Under the ACA, or Obamacare, however, private insurers had to cover "standard of care" costs of clinical trial participation as of 2014. For this study, the researchers analyzed more than 2,400 patient referrals to the Clinical Center for Targeted Therapy at ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Gleevec, Colorectal Cancer, Non-Small Cell Lung Cancer, Votrient, Tarceva, Tasigna, Avastin, Pancreatic Cancer, Sprycel, Sutent, Afinitor, Nexavar, Cisplatin, Carboplatin, Cytoxan, Erbitux

Doctors' Group Offers Ideas for Easing Cancer Costs

Posted 19 Jul 2017 by Drugs.com

WEDNESDAY, July 19, 2017 – New cancer drugs routinely cost $100,000 a year or more, and older cancer drugs are rising in price, too. Now, the American Society of Clinical Oncology (ASCO) has some suggestions for easing patients' money woes. The proposals include allowing Medicare to negotiate drug prices, legalizing the importation of drugs, and adopting bundled, or group, payment programs. In the new policy statement, ASCO also says it supports creation of a panel of "stakeholders" in health care to determine the effectiveness of its proposals. Such a group might also outline a uniform approach for assessing the value of drugs. "In what, undoubtedly, is one of the most difficult times in their lives, individuals with cancer should be focused on getting the best care possible, not worrying about financial strain on their families," said Dr. Clifford Hudis. He's CEO of ASCO, a leading ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Lupron, Medroxyprogesterone, Prostate Cancer, Tamoxifen, Arimidex, Lupron Depot, Fluorouracil, Femara, Lung Cancer, Gleevec, Colorectal Cancer, Brain Tumor, Anastrozole, Zoladex, Votrient

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, the clinical trials studied extended life by 3.34 million years, the study found. SWOG estimates the dollar return on investment from federal funding at $125 for each year of life gained. "A lot of people with cancer have lived longer because of the therapies tested in our publicly funded trials," study leader Joseph Unger said in a SWOG news release. He is an assistant member of the Fred Hutchinson Cancer Research Center's Cancer Prevention Program in Seattle. "At the same time, the cost of ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Lupron Depot, Fluorouracil, Femara, Lung Cancer, Gleevec, Colorectal Cancer, Rituxan, Isotretinoin

For Seniors, Treatment for One Eye Disease May Cause Another

Posted 16 Mar 2017 by Drugs.com

THURSDAY, March 16, 2017 – Drugs that preserve vision in people with the eye disease called age-related macular degeneration might increase the risk of another eye condition – glaucoma, a new study suggests. People who received at least seven eye injections of the drug bevacizumab (Avastin) each year to treat macular degeneration have a higher risk of eventually needing surgery to treat glaucoma, the Canadian study found. But, the researchers aren't suggesting that people forgo these treatments for macular degeneration. These drugs help stave off a previously untreatable cause of blindness in the elderly, and should continue to be used, the researchers said. And, if glaucoma does develop, treatments are available. "Even though there may be a risk here, this doesn't mean you should not be getting injections for macular degeneration," said study lead author Dr. Brennan Eadie. He's an ... Read more

Related support groups: Eye Conditions, Glaucoma, Macular Degeneration, Glaucoma (Open Angle), Votrient, Avastin, Sutent, Nexavar, Pazopanib, Stivarga, Sunitinib, Glaucoma/Intraocular Hypertension, Retinal Disorders, Cyramza, Retinopathy, Iclusig, Bevacizumab, Lenvima, Ramucirumab, Sorafenib

Cancer's Heavy Financial Burden

Posted 8 Jun 2016 by Drugs.com

WEDNESDAY, June 8, 2016 – Many cancer patients can't afford to see their doctor or take the medications they've been prescribed, a new study finds. And the problem will likely only get worse as the cost of cancer treatments continues to rise, the study authors said. "You can prescribe the best drug in the world, but if patients can't afford it and they can't get it, then it won't be effective," said study author Dr. Greg Knight. He is chief fellow with the University of North Carolina School of Medicine's division of hematology and oncology. "We saw a significant portion of patients in our study who were stretching their prescriptions or not coming to the doctor's office," Knight said in a university news release. The researchers reviewed survey results from nearly 2,000 patients at the N.C. Cancer Hospital in Chapel Hill, N.C. The participants were all 18 and older, and had been ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Gleevec, Colorectal Cancer, Brain Tumor, Votrient, Skin Cancer, Tarceva, Tasigna, Melanoma, Ovarian Cancer, Avastin, Nausea/Vomiting - Chemotherapy Induced, Endometrial Cancer, Sprycel, Sutent, Herceptin, Afinitor

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less able to afford cancer drugs than Americans, he said, even though U.S. monthly drug prices are about three to six times higher in the United States. That doesn't mean America came out on top in overall drug affordability, however. Developed nations such as Australia, England and Israel had the "best deal" in the world on cancer drugs, thanks to government programs that regulate drug pricing, the study found. "America is the wealthiest nation, but its drug prices are significantly higher – so much ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Lupron Depot, Tretinoin, Fluorouracil, Femara, Lung Cancer, Gleevec, Colorectal Cancer, Rituxan, Isotretinoin, Anastrozole

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Lupron Depot, Fluorouracil, Femara, Lung Cancer, Gleevec, Renal Cell Carcinoma, Colorectal Cancer, Basal Cell Carcinoma

Medicines Are Biggest Culprit in Fatal Allergic Reactions: Study

Posted 10 Oct 2014 by Drugs.com

THURSDAY, Oct. 9, 2014 – Although food allergies have garnered a lot of attention lately, a new study reports that medications are actually the biggest cause of sudden deaths related to allergy. Over a little more than a decade, nearly 60 percent of the allergy-related deaths were caused by medications, while less than 7 percent were caused by food allergies, the study found. "Medications can be dangerous," said study researcher Dr. Elina Jerschow, director of the Drug Allergy Center at Montefiore Medical Center and assistant professor of medicine at Albert Einstein College of Medicine, in New York City. While research from other countries has reported medications as a major culprit in anaphylaxis-related deaths, Jerschow said, the problem has been less defined in the United States. One reason is that there is no national registry for anaphylaxis deaths, she said. The study was ... Read more

Related support groups: Provera, Depo-Provera, Amoxicillin, Metronidazole, Doxycycline, Clindamycin, Methotrexate, Cephalexin, Penicillin, Azithromycin, Bactrim, Cipro, Accutane, Lupron, Ciprofloxacin, Flagyl, Augmentin, Levaquin, Keflex, Medroxyprogesterone

New Drug May Slow Advanced Ovarian Cancer

Posted 3 Jun 2013 by Drugs.com

SATURDAY, June 1 – Women with advanced ovarian cancer stayed in remission almost six months longer when they were treated with the targeted drug pazopanib (Votrient), new German research says. "Our findings show that we finally have a drug that can maintain control over ovarian cancer growth achieved through initial treatments," study author Dr. Andreas du Bois, a professor of gynecologic oncology at Kliniken Essen-Mitte in Essen, said in a statement. "If pazopanib is approved for ovarian cancer, many patients will experience longer disease-free and chemotherapy-free periods. During this time, the patient keeps control over the disease, instead of the disease having control over patient's life." The results were to be presented Saturday at the American Society of Clinical Oncology annual meeting, in Chicago. Research presented at medical meetings is considered preliminary until ... Read more

Related support groups: Votrient, Ovarian Cancer, Pazopanib

Cancer Chemotherapy Tied to Slight Rise in Risk for Leukemia

Posted 14 Feb 2013 by Drugs.com

THURSDAY, Feb. 14 – Chemotherapy can be a lifesaver for thousands of cancer patients, but a new study suggests that it might slightly raise the odds for a type of leukemia later in life. Over the past 30 years, the risk for acute myeloid leukemia (AML) has increased for patients who underwent chemotherapy for certain forms of cancer, particularly non-Hodgkin lymphoma, the new study found. On the other hand, the researchers from the U.S. National Cancer Institute said other cancer survivors may have a reduced risk for AML due to a change in chemotherapy agents that occurred decades ago. One expert not connected to the study stressed that cancer patients need to put the findings into perspective. "It's important to realize that the risk of developing acute myeloid leukemia related to prior chemotherapy is small and increases with the number of chemotherapy treatments given over time," ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Accutane, Lupron, Medroxyprogesterone, Tamoxifen, Arimidex, Tretinoin, Lupron Depot, Fluorouracil, Femara, Gleevec, Rituxan, Isotretinoin, Anastrozole, Zoladex, Votrient, Claravis

Long-Term Side Effects Key When Cancer Patients Choose Drugs

Posted 4 Jun 2012 by Drugs.com

SATURDAY, June 2 – Long-term medication side effects such as fatigue can be key for patients deciding which cancer drug to take, new research suggests. In the study, people with advanced kidney cancer preferred pazopanib (Votrient) over sunitinib (Sutent), according to a randomized controlled trial funded by the makers of pazopanib. Although doctors may not see a big difference between the two U.S. Food and Drug Administration-approved drugs for the long-term treatment of kidney cancer that has metastasized (spread to other organs), researchers from France found that patients felt Votrient left them less fatigued and with a better quality of life, according to the study. "While we expected patients would prefer one drug over the other, due to the known toxicity profiles, we didn't expect this great a preference," lead study author Dr. Bernard Escudier, a physician at the Institut ... Read more

Related support groups: Cancer, Votrient, Sutent, Pazopanib, Sunitinib

Votrient Approved to Treat Cancer That Begins in Soft Tissue

Posted 27 Apr 2012 by Drugs.com

FRIDAY, April 27 – Votrient (pazopanib) has been approved by the U.S. Food and Drug Administration to treat people with soft tissue sarcoma that have received previous chemotherapy. This type of tumor originates in soft tissue such as a muscle, fat, or fibrous tissue, the agency said in a news release. About 10,000 cases of soft tissue sarcoma are reported each year in the United States. Votrient works by inhibiting angiogenisis, the production of new blood vessels that fuel tumor growth. The drug's safety and effectiveness were evaluated in clinical studies involving 369 people with soft tissue sarcoma who had undergone chemotherapy. Among people who took Votrient, the disease didn't progress for an average of 4.6 months, compared to 1.6 months among people who took an inactive placebo. The most common side effects of Votrient included fatigue, diarrhea, nausea, weight loss, high ... Read more

Related support groups: Votrient, Pazopanib, Soft Tissue Sarcoma

FDA Approves Votrient for Advanced Soft Tissue Sarcoma

Posted 26 Apr 2012 by Drugs.com

April 26, 2012 – The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues. Votrient is a pill that works by interfering with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive. A rare cancer with many subtypes, soft tissue sarcoma occurs in about 10,000 cases annually in the United States. More than 20 subtypes of sarcoma were included in the clinical trial leading to approval of Votrient. The drug is not approved for patients with adipocytic soft tissue sarcoma and gastrointestinal stromal tumors. "Soft tissue sarcomas are a diverse group of tumors and the approval of Votrient for this general class of tumors is the first in decades," ... Read more

Related support groups: Votrient, Pazopanib, Soft Tissue Sarcoma

Certain Cancer Drugs May Have Fatal Side Effects: Analysis

Posted 6 Feb 2012 by Drugs.com

MONDAY, Feb. 6 – Treatment with three relatively new cancer drugs may be linked to a slightly increased risk of death, a new analysis suggests. While the risk is low, it should be taken into account by doctors and patients, according to Dana-Farber Cancer Institute scientists and colleagues. The investigators analyzed the findings of 10 clinical trials that included nearly 4,700 patients treated with sorafenib (Nexavar) for kidney and liver cancer; sunitinib (Sutent) for kidney cancer and gastrointestinal stromal tumor; or pazopanib (Votrient) for kidney cancer. These so-called "targeted" drugs are used to stop the growth or spread of cancer by blocking the vascular endothelial growth factor tyrosine kinase receptors in cancer cells, the researchers explained in a Dana-Farber news release. The analysis of the clinical trials revealed that the incidence of fatal complications was 1.5 ... Read more

Related support groups: Votrient, Sutent, Nexavar, Pazopanib, Sunitinib, Sorafenib

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Renal Cell Carcinoma, Soft Tissue Sarcoma

Votrient Patient Information at Drugs.com